Juan Luis Steegmann

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text

Medicine, Oncology, Pharmacology +9

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio et al. · Blood · 2013 · 391 citations · Full text

Medicine, Hematology, Oncology +8

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Satu Mustjoki, Marja Ekblom, T. Petteri Arstila et al. · Leukemia · 2009 · 320 citations

Life Sciences, Immunology, Oncology +14

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud et al. · Leukemia · 2020 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

Alberto Álvarez‐Larrán, Manuel Pérez‐Encinas, Francisca Ferrer‐Marín et al. · Haematologica · 2016 · 74 citations · Full text

Medicine, Hematology, Pharmacotherapy +11